Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules India Limited Received ANDA Approval for Pantoprazole Sod Delayed-Release Tablets
Details : Pantoprazole Sodium Delayed-Release tablets are indicated for short-term treatment of Erosive Esophagitis Associated with GERD and Pathological Hypersecretory Conditions.
Product Name : Protonix-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2023
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 26, 2011
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 26, 2011
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic announces USFDA final approval for Pantoprazole Sodium for Injection, 40 mg/vial
Details : Protonix IV-Generic is a potassium-transporting ATPase inhibitor, small molecule drug candidate, which is indicated for the treatment of gastroesophageal reflux disease.
Product Name : Protonix IV-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 03, 2025
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pantoprazole Sodium,Domperidone
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Royal Sense Launches Multiple Products in Pharmaceutical Category
Details : OPENTOP D (pantoprazole Sodium and domperidone) Delayed-Release tablets are indicated for short-term treatment of Erosive Esophagitis Associated with GERD.
Product Name : Opentop D
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2024
Lead Product(s) : Pantoprazole Sodium,Domperidone
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2021
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Civica Rx
Deal Size : Undisclosed
Deal Type : Collaboration
Sandoz Ships First Medicine in Collaboration with Civica Rx to Supply Us Hospitals
Details : Sandoz has shipped pantoprazole sodium for injection, 40 mg to Civica Rx to supply the hospitals it serves as part of a multiyear collaboration to help reduce supply shortages, with several other medicines on the way before the end of the year.
Product Name : Pantoprazole Sodium-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 11, 2020
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Civica Rx
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Dong-A ST Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of DA-5204 on Gastroesophageal Reflux Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2019
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Dong-A ST Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Canadian Institutes of Health Research | Canadian Critical Care Trials Group | Australian and New Zealand Intensive Care Society Clinical Trials Group | National Health and Medical Research Council, Australia
Deal Size : Inapplicable
Deal Type : Inapplicable
Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2017
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Canadian Institutes of Health Research | Canadian Critical Care Trials Group | Australian and New Zealand Intensive Care Society Clinical Trials Group | National Health and Medical Research Council, Australia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Hospital Ángeles, Clínica Londres, Mexico City | Centro InmunoQ | Torre Mayo | Hospital Ángeles Metropolitano, Mexico City | Centro Médico ABC
Deal Size : Inapplicable
Deal Type : Inapplicable
Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2016
Lead Product(s) : Pantoprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Hospital Ángeles, Clínica Londres, Mexico City | Centro InmunoQ | Torre Mayo | Hospital Ángeles Metropolitano, Mexico City | Centro Médico ABC
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
